In pharma, similar names kill people. The Supreme Court’s Cadila test runs stricter here than anywhere else.
Pharma is the one Indian industry where trademark law is harshest — and rightly so. The Supreme Court in Cadila Health Care v. Cadila Pharmaceuticals (2001) set the seven-factor test for trademark similarity, applied with extra rigour to medicines because confusion can be fatal.
For a pharma company in India, brand-name selection is an IP exercise, a DCGI compliance exercise and a public-safety exercise at the same time. Getting it wrong means a Section 11 refusal, a recall, or a court order.
Three filings cover most of the IP risk on day one. Each is a standalone service and each links to a deeper walkthrough.
Class 5 covers pharmaceuticals, medicinal preparations, dietary supplements, sanitary preparations, dental and veterinary products. Almost every pharma trademark filing in India starts here.
The brand-name screen is unlike any other category. The Cadila judgment requires: examining the nature of the goods (Schedule H, prescription-only, OTC), the class of consumers, the mode of purchase, the visual and phonetic similarity, the structural similarity of the words, the meaning, and any other surrounding circumstances. Two names that would pass for shampoo will fail for pharmaceuticals.
The Cadila judgment itself involved ‘Falcitab’ and ‘Falcigo’ — both antimalarial drugs with similar molecules. The Supreme Court held that phonetic similarity in pharmaceuticals carries higher risk and lower tolerance.
The Drugs Controller General of India (DCGI) maintains its own brand-name register under the Drugs and Cosmetics Act, 1940 and Rule 96 of the Drugs Rules, 1945. A trademark registration does not auto-clear DCGI; DCGI checks for confusion with existing approved brand names. Both filings need to align.
Practical sequence: trademark search first, then DCGI brand search, then file the trademark, then the DCGI brand approval. Filing in the reverse order is the most common reason pharma brand launches stall.
The molecule name is generic and cannot be trademarked — paracetamol, metformin, atorvastatin are common property. The branded name can. Companies often hold the brand-name trademark plus copyright in the carton artwork and the package insert. Together they make counterfeit enforcement workable.
Launching a new molecule? Brand screening before DCGI saves the recall risk.
WhatsApp our team →Class 5 covers pharmaceuticals, medicinal preparations, dietary supplements and veterinary products. Some companies also file in Class 3 (cosmetics with medicinal claims) and Class 10 (medical devices).
The Supreme Court in Cadila v. Cadila (2001) listed seven factors: nature of the goods, class of consumers, mode of purchase, structural and phonetic similarity of the marks, similarity of the ideas conveyed, and any other surrounding circumstance. The test is applied with extra rigour to medicines.
No. The Trade Marks Registry and DCGI run separate registers under different statutes. A trademark registration does not automatically clear DCGI brand-name approval, and DCGI approval does not give trademark rights. Both filings are needed for full protection.
No. Molecule names (INNs) are public property and cannot be monopolised under Section 9. Only the proprietary brand name layered over the molecule is trademarkable.